SEC Form 4 · accession 0000899243-16-028304
Sagent Pharmaceuticals, Inc. · SGNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean Brynjelsen
Officer — EVP, Business Development
Period of report
Aug 29, 2016
Accepted (ET)
Aug 31, 2016 · 6:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 29, 2016 | D | 9,844 | $21.75 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option to BuyF2 | $12.19 | Aug 29, 2016 | D | 21,016 | D | — | Apr 4, 2026 | Common Stock | 21,016 | 0 | D |
Explanation of responses
- F1Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these restricted shares were canceled and converted into the right to receive $21.75 per share, without interest, less any applicable withholding taxes (the "Merger Consideration").
- F2Represents the disposition of options, which provided for vesting in four equal installments beginning April 4, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $9.56 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration.